Department of Psychiatry and Psychotherapy, Jena University Hospital, Jena, Germany; Center for Intervention and Research on Adaptive and Maladaptive Brain Circuits Underlying Mental Health (C-I-R-C), Jena-Magdeburg-Halle, Germany.
Department of Psychiatry and Psychotherapy, Jena University Hospital, Jena, Germany; Center for Intervention and Research on Adaptive and Maladaptive Brain Circuits Underlying Mental Health (C-I-R-C), Jena-Magdeburg-Halle, Germany; Clinical Affective Neuroimaging Laboratory (CANLAB), Magdeburg, Germany.
Neuropharmacology. 2023 Sep 1;235:109568. doi: 10.1016/j.neuropharm.2023.109568. Epub 2023 May 12.
Depression is highly prevalent (6% 1-year prevalence) and is the second leading cause of disability worldwide. Available treatment options for depression are far from optimal, with response rates only around 50%. This is most likely related to a heterogeneous clinical presentation of major depression disorder (MDD), suggesting different manifestations of underlying pathophysiological mechanisms. Poorer treatment outcomes to first-line antidepressants were reported in MDD patients endorsing an "atypical" symptom profile that is characterized by preserved reactivity in mood, increased appetite, hypersomnia, a heavy sensation in the limbs, and interpersonal rejection sensitivity. In recent years, evidence has emerged that immunometabolic biological dysregulation is an important underlying pathophysiological mechanism in depression, which maps more consistently to atypical features. In the last few years human microbial residents have emerged as a key influencing variable associated with immunometabolic dysregulations in depression. The microbiome plays a critical role in the training and development of key components of the host's innate and adaptive immune systems, while the immune system orchestrates the maintenance of key features of the host-microbe symbiosis. Moreover, by being a metabolically active ecosystem commensal microbes may have a huge impact on signaling pathways, involved in underlying mechanisms leading to atypical depressive symptoms. In this review, we discuss the interplay between the microbiome and immunometabolic imbalance in the context of atypical depressive symptoms. Although research in this field is in its infancy, targeting biological determinants in more homogeneous clinical presentations of MDD may offer new avenues for the development of novel therapeutic strategies for treatment-resistant depression. This article is part of the Special Issue on "Microbiome & the Brain: Mechanisms & Maladies".
抑郁症的发病率很高(1 年患病率为 6%),是全球第二大致残原因。现有的抑郁症治疗选择远非最佳,反应率仅约为 50%。这很可能与重度抑郁症(MDD)的临床表现异质性有关,表明潜在病理生理机制存在不同表现。在表现出“非典型”症状特征的 MDD 患者中,一线抗抑郁药的治疗效果更差,这些特征包括情绪反应保持、食欲增加、嗜睡、四肢沉重感和人际拒绝敏感性。近年来,有证据表明免疫代谢生物失调是抑郁症的一个重要潜在病理生理机制,它与非典型特征更一致。在过去几年中,人类微生物居民已成为与抑郁症免疫代谢失调相关的一个关键影响变量。微生物组在宿主固有和适应性免疫系统的关键组成部分的训练和发育中起着关键作用,而免疫系统则协调宿主-微生物共生的关键特征的维持。此外,作为一个代谢活跃的共生生态系统,共生微生物可能对信号通路产生巨大影响,这些信号通路参与导致非典型抑郁症状的潜在机制。在这篇综述中,我们讨论了微生物组与免疫代谢失衡在非典型抑郁症状中的相互作用。尽管该领域的研究仍处于起步阶段,但针对 MDD 更同质临床表现中的生物学决定因素可能为开发治疗难治性抑郁症的新治疗策略提供新途径。本文是“微生物组与大脑:机制与疾病”特刊的一部分。